Contemporary pharmaceutical and cosmetic products, particularly dispersed systems, necessitate precise control over their physicochemical characteristics. Particle size is a critical factor that substantially affects the bioavailability, stability, and overall efficacy of formulations. In this study, the “Emulzamaj” cosmetic preparation (composition 1) was analyzed using the Nanosizer NS300 (Malvern) to determine the size distribution of dispersed phases, polydispersity index (PDI), diffusion coefficient, and colloidal stability. The dispersed phase particles exhibited an average diameter of 1,149.64 nm, a PDI of 0.378, and a diffusion coefficient of 2.13 × 10⁻⁹ cm²/s. The measured zeta potential of 37.70 mV indicates good electrokinetic stability, suggesting the formulation is suitable for prolonged shelf-life and enhanced performance in cosmetic applications. These findings provide valuable insights into the formulation design and quality control of complex emulsion-based cosmetic systems.

Myasthenia gravis is considered an autoimmune disease of the respiratory tract and muscle weakness of the body associated with the formation of antibodies against acetylcholine receptors (AChR) or related proteins (MuSK, lrp4, etc.) in the postsynaptic neuromuscular junction. Inflammatory and immunological mechanisms play an important role in the pathogenesis of MG; this article analyzes specifically inflammatory cellular processes, cytokines, and plasma mediators. It is known that the development of myasthenia gravis is not a full-fledged autoimmune disease, and the involvement of various cytokines in the pathogenesis has shown that the inflammatory process is at the heart of the disease